Utility of ICG in Benign Bone Tumors

Completed · Early Phase 1

Conditions studied: Bone Tumor

In brief

Patients with a biopsy-proven benign bone tumor for which standard of care is intralesional operative management will receive a weight-appropriate IV dose of indocyanine green (ICG, FDA-approved) the day prior to surgery during their standard pre-operative clinic visit. On the day of surgery, fluorescence images will be obtained using a non-invasive fluorescence camera.

Key facts

Study ID

NCT05075889

Run by

Dartmouth-Hitchcock Medical Center

People needed

2

Starts

2021-11-11

Expected to finish

2022-04-20

Last updated by the study team

2024-05-14

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects 12 years of age or older
• Diagnosis of any of the following that has been identified by imaging and/or biopsy:
• Enchondroma
• Periosteal chondroma
• Osteochondroma
• Chondroblastoma
• Giant cell tumor of bone
• Aneurysmal bone cyst
• Unicameral (aka Simple) bone cyst
• Chondromyxoid fibroma
• Osteoblastoma
• Desmoplastic fibroma
• Fibrous dysplasia
• Osteofibrous dysplasia
• Intralesional operative management for their tumor planned
• Written informed consent signed by the subject if 18 years of age or older or by parent(s) or legally authorized representative if younger than 18 years of age. If younger than 18 years of age, the child must be able to be assent.

You may not qualify if…

• Iodine allergy
• Women who are pregnant or breastfeeding
• Incarcerated individuals

Where it is running

• Dartmouth-Hitchock — Lebanon, New Hampshire, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.